GLP-1 trends 2025: real-world data, patient outcomes & future therapies
Few areas of medicine have captured public interest over the past two years quite like...
Few areas of medicine have captured public interest over the past two years quite like...
AI-driven mortality models are supposed to provide accurate, data-backed insights into patient...
GLP-1 Trends: Ozempic and Semaglutide drive a 587% spike in prescriptions Prescriptions for GLP-1...
FDA's AI guidance is reshaping real-world data standards Artificial Intelligence (AI) is rapidly...
HealthVerity COO Andrew Goldberg recently sat down with Quest Diagnostics’ Director, Health...
With advances in artificial intelligence (AI) making headlines almost daily, the life sciences...
An interview with Kristijan Kahler, executive director of innovation evidence at Novartis While...
Given its role at the intersection of novel real-world data and emerging technologies, HealthVerity...
HealthVerity is proud to partner with Inovalon, the largest closed claims data source in the U.S.,...
One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime, that’s one...
Few areas of medicine have captured public interest over the past two years quite like glucagon-like peptide-1 (GLP-1) receptor agonists. Originally developed to improve glycemic control in type 2 diabetes, drugs like semaglutide (Ozempic/Wegovy) and...